Novavax Collects $125M as Sanofi Starts Phase 3 Combo Vaccine Trial in Europe
NVAX sits 68% above its 52-week low of $6.2 on light trading volume (0.1× avg).
Summary
Novavax booked a $125 million milestone payment after partner Sanofi launched a Phase 3 trial in Europe for an influenza-Covid-19 combination vaccine. That cash lands against a company that posted a $53.4 million net loss in Q2 and is leaning on partnership revenue while its own product sales shrink. Two more payments are stacked behind it: $75 million on tech transfer in mid-2027 and $225 million if the combo vaccine launches in the U.S. The $125 million is roughly half of the $235M-$275M full-year revenue guidance Novavax reaffirmed in August, so it is a meaningful addition to the top line rather than a rounding error. The stock also carries the overhang of Shah Capital's October exit from its activist stake, which removed a push for leadership and buyback changes. Watch the Phase 3 timeline and the mid-2027 tech-transfer milestone, which is the next scheduled cash trigger.
At the time of this announcement, NVAX was trading at $10.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $6.20 to $13.39. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.